SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

NUZYRA

ZLAB·Zai Lab Ltd
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercialized. NUZYRA has been marketed in China since December 2021 and in the US since October 2018.
Why 4/10
NUZYRA is already approved and commercially marketed in both the US (FDA 2018) and China (NMPA 2021) with no pending regulatory decision or pivotal readout. The next hard catalyst for Zai Lab overall is the November 30, 2026 PDUFA for povetacicept (a different drug). NUZYRA itself has no scheduled binary event in the next 12 months, capping the impact score at 4.
Actionable Insight NEUTRAL

NUZYRA itself has no upcoming binary catalyst; it is an approved, marketed product contributing steady growth. The next major catalyst for Zai Lab is the November 30, 2026 PDUFA for povetacicept in IgAN, a separate drug. Watch Q4 2026 earnings for NUZYRA's continued NRDL-driven sales trajectory and any label-expansion developments in China.

Price Chart

Loading chart...

Executive Summary

NUZYRA (omadacycline) is a broad-spectrum antibiotic that Zai Lab (ZLAB) exclusively licenses for Greater China from Paratek Pharmaceuticals (now owned by Novo Holdings). Originally FDA-approved in the US in 2018, it was approved by China's NMPA in December 2021 as a Category 1 innovative drug for community-acquired bacterial pneumonia (CABP) and acute bacterial skin infections (ABSSSI). Zai Lab launched it commercially in mainland China and Macau, and it was renewed in China's 2025 National Reimbursement Drug List (NRDL). In Q3 2026, NUZYRA was cited as a key growth driver for Zai Lab's product revenue. The drug is one of eight commercial products in Zai Lab's portfolio and has no upcoming binary regulatory catalyst, making it a steady but non-pivotal contributor to the company's value.

How It Works

NUZYRA (omadacycline) is a broad-spectrum antibiotic in the tetracycline class, specifically an aminomethylcycline. It works by stopping bacteria from making proteins they need to grow and multiply. It can be given as a pill or through an IV, making it flexible for treating lung infections (pneumonia) and serious skin infections in adults. It is designed to work against bacteria that have become resistant to older tetracycline antibiotics.

Trial Status

NUZYRA is approved and commercially marketed in both the US (FDA, October 2018) and China (NMPA, December 2021) for CABP and ABSSSI. Zai Lab is conducting real-world evidence studies in China. Separately, Paratek (the originator) is exploring omadacycline in Phase 2 studies for nontuberculous mycobacterial (NTM) pulmonary disease and bone/joint infections, but these are not part of Zai Lab's current China-focused program.

The Two-Sided Case

▲ Bull Case4
NUZYRA is already approved and commercialized in China (NMPA Category 1 innovative drug, December 2021) with both oral and IV formulations for CABP and ABSSSI, removing regulatory risk.
NUZYRA was renewed in China's 2025 National Reimbursement Drug List (NRDL), ensuring continued patient access and volume growth through government reimbursement.
In Q3 2026, NUZYRA was cited as a key driver of Zai Lab's sequential product revenue growth, supported by increased market coverage and penetration.
Zai Lab has an exclusive license for Greater China from Paratek (now owned by Novo Holdings), and the drug is locally manufactured in China, providing supply chain advantages.
▼ Bear Case4
NUZYRA is one of eight commercial products in Zai Lab's portfolio and is not the dominant revenue driver; its contribution is modest relative to the overall business.
As a tetracycline-class antibiotic, NUZYRA faces generic competition risk in China as patent protection erodes, and competition from established antibiotics could limit market share.
Antimicrobial stewardship policies in China aimed at curbing antibiotic overuse may restrict broad application of NUZYRA, capping growth potential.
Zai Lab's Q3 2026 total revenue fell to $108.2M from $116.1M a year earlier, and the company posted a net loss, highlighting that NUZYRA's growth is partially offset by declines in other products like Optune.

Upcoming Catalysts

  • No upcoming binary catalyst specific to NUZYRA. The drug is already approved and commercialized. Zai Lab's next major catalyst is the November 30, 2026 PDUFA for povetacicept (IgAN), a separate drug.
  • Q4 2026 earnings (expected early 2027) will show continued NRDL-driven sales trajectory for NUZYRA.
  • Potential label expansion in China for additional indications (e.g., bone/joint infections) if Zai Lab pursues supplemental NDA filings.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Zai Lab Ltd 8-K ZLAB ·Originating report

Sources · 12

Hover a chip for the title
1 zailaboratory.com2 zailab.gcs-web.com3 flcube.com4 businesswire.com5 flcube.com6 biospace.com7 biospace.com8 zailaboratory.com9 accessdata.fda.gov10 drugs.com11 sec.gov12 hkexnews.hk